Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22208862 | 0.89 | LCK (0.61) | HSD17B2DPP4CA12CA1CA2 | |
| SCHEMBL27455432 | 0.85 | HSD17B2 (0.59) | HSD17B2DPP4CA12CA1CA2 | |
| SCHEMBL22208578 | 0.85 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6859316 | 0.84 | KMT2A (0.54) | HSD17B2DPP4LCKFYNLMNA | |
| SCHEMBL13468453 | 0.84 | HSD17B2 (0.62) | HSD17B2DPP4CA12CA1CA2 | |
| SCHEMBL24379203 | 0.83 | LCK (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1301113 | 0.83 | LCK (0.48) | HSD17B2DPP4CA12CA1CA2 | |
| SCHEMBL13469249 | 0.83 | HSD17B2 (0.56) | HSD17B2DPP4CA12CA1CA2 | |
| SCHEMBL12109024 | 0.82 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28097982 | 0.81 | HSD17B2 (0.55) | HSD17B2DPP4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179087-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | Immunophage Biotech (Shanghai) Co., Ltd. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-119403800-A | Compounds and their use as LPAR5 antagonists | 艾美斐生物医药科技(上海)有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4486742-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUNOPHAGE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023165591-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUTHER PHARMATECH (SHANGHAI) CO., LTD. (CN) | 2023-09-07 | — | — | WO | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231665-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009089263-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | HSD17B2 1203/4885DPP4 1648/4885CA12 4642/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | HSD17B2 1203/4885DPP4 1648/4885CA12 4642/4885 |
| US-20250179087-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | LPAR5, LPAR3, LPAR2 | HSD17B2 2314/4885DPP4 814/4885CA12 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.